A stage-gated roadmap for inquiry-only CBD, CBG, and CBN private-label concepts with zero formulated THC and document review.
A responsible private-label hemp project starts with regulatory scope and documentation, not a production quantity. This company's concepts are limited to CBD, CBG, and CBN formats with a zero formulated THC target. They are inquiry-only until the formula, manufacturer, final label, packaging, and finished-lot COA are reviewed.
1. Write a narrow product brief
Define the format, ingredients, package size, unit count, labeled cannabinoid amount, intended Virginia sales channel, and shelf-life target. Keep claims factual and avoid statements that a product diagnoses, treats, cures, or prevents a disease. Also avoid promising a particular physical or mental outcome.
2. Select documented inputs
Request lot-specific COAs and specifications for CBD, CBG, CBN, carriers, flavors, and other ingredients. “Zero formulated THC” means no THC ingredient is intentionally included; it does not eliminate the need to test for trace total THC in the completed package.
3. Review the manufacturer and formula
Confirm the legal business identity, facility information, quality procedures, allergen controls, complaint process, recall contacts, and records available for the relevant format. Freeze a formula version before label review so ingredient and cannabinoid declarations remain aligned.
4. Build packaging around dated limits
Virginia's ceiling became 2 mg total THC per package on August 15, 2026, and the former 25:1 allowance was repealed. A stricter federal definition change is scheduled for November 12, 2026: final hemp-derived cannabinoid products containing more than 0.4 mg total THC per container would be excluded. Package size and count therefore matter. This catalog's conservative position is a non-detect finished-package target rather than formulating up to either ceiling.
5. Approve final artwork
Check identity statement, net contents, ingredient and allergen information, business details, lot coding, cannabinoid amounts, warnings, and any required directions. Review trademarks and packaging appearance. Child-appealing imitation, unsupported certifications, and unqualified health claims create avoidable risk.
6. Test and release the finished lot
Set a written sample and retention plan. Match the laboratory report to the exact lot and finished package. Do not release a production lot merely because a pilot, ingredient, or prior batch passed. Keep signed approval records and a process for quarantine, investigation, and disposition when criteria are not met.
7. Treat pricing as a quote, not a promise
Tooling, testing, packaging, freight, design, and quantity all affect cost. Request an itemized quote and evaluate it against a conservative demand forecast. No particular margin or sell-through rate should be assumed.
Regulatory note: Private-label compliance is fact-specific. This roadmap is not legal advice; obtain current legal and regulatory review before production or distribution.
For current product-screening context, review our Virginia hemp compliance requirements and browse THC-free hemp gummies.